PubMed ID:
19022547
Public Release Type:
Journal
Publication Year: 2009
Affiliation: Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903, USA.
DOI:
https://doi.org/10.1053/j.ajkd.2008.08.010
Authors:
Adey D,
Alfrey E,
Anil Kumar MS,
Bolin P Jr,
Bostom A,
Bostom AG,
Bresnahan B,
Bunnapradist M,
Carpenter MA,
Cole E,
Conti D,
Cosio F,
Danovitch G,
Fabrega A,
FAVORIT Study Investigators,
Gallon L,
House A,
Hunsicker L,
Hunsicker L,
Jacques PF,
Kasiske B,
Kew C,
Koch M,
Kusek JW,
Levey AS,
Markell M,
Matas A,
McKenney JL,
Mercier RY,
Norman D,
Ojo A,
Pacheco-Silva A,
Pesavento T,
Pfeffer MA,
Pirsch J,
Selhub J,
Singh A,
Smith S,
Vella J,
Weir M,
Yaqub MS
Studies:
Folic Acid for Vascular Outcome Reduction in Transplantation Trial
Hyperhomocysteinemia may be a modifiable risk factor for the prevention of arteriosclerotic outcomes in patients with chronic kidney disease (CKD). Few clinical trials of homocysteine lowering have been conducted in persons with CKD before reaching end-stage renal disease. Kidney transplant recipients are considered individuals with CKD.